Otitis Media and URI with MCC DRG

DRG 152 encompasses inpatient stays for otitis media and upper respiratory infection when a Major Complication or Comorbidity is present, increasing clinical complexity. Understanding this Diagnosis-Related Group matters for inpatient reimbursement because the Major Complication or Comorbidity designation raises resource intensity and influences Medicare payment under the inpatient prospective payment system.

DRG 152 Overview

DRG 152 covers inpatient admissions for otitis media and upper respiratory infections with at least one Major Complication or Comorbidity present. This Diagnosis-Related Group groups patients whose clinical complexity increases resource use and payment relative to cases without major complications. It is important for Medicare payment because the presence of a Major Complication or Comorbidity elevates the relative weight and influences hospital reimbursement under Medicare Severity Diagnosis-Related Group methodology. Accurate clinical documentation and coding determine assignment to this DRG and thus affect payment.

Acute inpatient antimicrobial strategy trials: studies comparing different empirical antibiotic regimens, dosing strategies, or routes (intravenous versus early switch to oral) for hospitalized children and adults admitted with severe otitis media or upper respiratory infection complications with major complications or comorbidities (the MCC population). These trials focus on time to clinical improvement, resolution of complication (eg, mastoiditis, meningitis, severe pneumonia), length of stay, and adverse events in medically complex patients. Results inform providers about safe, effective inpatient treatment algorithms and help payers evaluate cost-effective antibiotic stewardship and stewardship-driven length-of-stay reductions.
Comparative effectiveness and surgical timing studies: pragmatic trials or cohort studies assessing outcomes of medical management versus surgical interventions (for example tympanostomy tube placement or drainage procedures) and optimal timing of such procedures in patients with otitis media complicated by major comorbidities or refractory upper respiratory infection sequelae. These investigations enroll hospitalized patients who have failed initial medical therapy or who have anatomical or systemic risk factors and compare rates of complication resolution, readmission, and functional outcomes. Evidence guides clinicians on indications and timing for procedures in higher-risk inpatients and helps payers understand downstream utilization and potential cost offsets from timely intervention.
Post-discharge outcomes and readmission prevention studies: prospective observational studies and quality-improvement trials that follow discharged patients with prior hospitalization for complicated otitis media or severe URI to assess readmission drivers, outpatient recurrence, functional recovery, antibiotic-related adverse events, and adherence to follow-up care. These studies often target high-risk subgroups (young children, elderly, immunocompromised, or those with multiple chronic conditions) to evaluate transitional care interventions such as early outpatient follow-up, telehealth monitoring, or home nursing support. Findings are relevant to providers for optimizing discharge planning and to payers for designing bundled-payment or care-management programs that reduce preventable readmissions and total episode costs.

Acute inpatient antimicrobial strategy trials: studies comparing different empirical antibiotic regimens, dosing strategies, or routes (intravenous versus early switch to oral) for hospitalized children and adults admitted with severe otitis media or upper respiratory infection complications with major complications or comorbidities (the MCC population). These trials focus on time to clinical improvement, resolution of complication (eg, mastoiditis, meningitis, severe pneumonia), length of stay, and adverse events in medically complex patients. Results inform providers about safe, effective inpatient treatment algorithms and help payers evaluate cost-effective antibiotic stewardship and stewardship-driven length-of-stay reductions.
Comparative effectiveness and surgical timing studies: pragmatic trials or cohort studies assessing outcomes of medical management versus surgical interventions (for example tympanostomy tube placement or drainage procedures) and optimal timing of such procedures in patients with otitis media complicated by major comorbidities or refractory upper respiratory infection sequelae. These investigations enroll hospitalized patients who have failed initial medical therapy or who have anatomical or systemic risk factors and compare rates of complication resolution, readmission, and functional outcomes. Evidence guides clinicians on indications and timing for procedures in higher-risk inpatients and helps payers understand downstream utilization and potential cost offsets from timely intervention.
Post-discharge outcomes and readmission prevention studies: prospective observational studies and quality-improvement trials that follow discharged patients with prior hospitalization for complicated otitis media or severe URI to assess readmission drivers, outpatient recurrence, functional recovery, antibiotic-related adverse events, and adherence to follow-up care. These studies often target high-risk subgroups (young children, elderly, immunocompromised, or those with multiple chronic conditions) to evaluate transitional care interventions such as early outpatient follow-up, telehealth monitoring, or home nursing support. Findings are relevant to providers for optimizing discharge planning and to payers for designing bundled-payment or care-management programs that reduce preventable readmissions and total episode costs.

OpenPayer

Summary & Overview

Otitis Media and URI with MCC: Inpatient Reimbursement Overview

DRG 152 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes